Canaccord raised the firm’s price target on Century Therapeutics to $24 from $22 and keeps a Buy rating on the shares. The firm said the company reported Q4 results and there were no surprises, as they continue to look toward a mid-year update from the Ph1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory B-cell lymphomas.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IPSC:
- Century Therapeutics Updates Investor Presentation Materials
- Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
- IPSC Earnings this Week: How Will it Perform?
- Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
